Key result
Statin use is linked to ~48% lower odds of high-grade prostate cancer.
Why the study?
Does the use of statins reduce the risk of prostate cancer in adult men?
Case-Control (n=1,698)
Does the use of statins reduce the risk of prostate cancer in adult men?
Answers are grounded in this paper and cite their sources.
Long-term use of lipophilic statins is associated with a significantly reduced risk of high-grade prostate cancer.
BACKGROUND: Antilipemic drugs have been hypothesized to decrease the risk of several cancers; however, results are still conflicting for prostate cancer. METHODS: We used data from the EPICAP study, a French population-based case-control study including 819 incident prostate cancer cases and 879 population-based controls frequency-matched by age. Detailed information on the use of antilipemic drugs has been collected. RESULTS: The use of overall antilipemic drugs was not associated with prostate cancer risk, whereas the use of statins, and particularly lipophilic statins, was inversely associated with high-grade prostate cancer with an International Society of Urological Pathology score ≥4 [OR = 0.52; 95% confidence interval (CI), 0.27-1.00; OR = 0.30; 95% CI, 0.12-0.77, respectively]. When taking into account the duration of use, long duration (≥10 years) of statin and lipophilic statin was inversely associated with prostate cancer overall (OR = 0.69; 95% CI, 0.47-1.01; OR = 0.54; 95% CI, 0.35-0.85, respectively) and with high-grade prostate cancer (OR = 0.49; 95% CI, 0.24-1.01; OR = 0.26, 95% CI, 0.09-0.72, respectively). CONCLUSIONS: Our results showed an inverse association between high-grade prostate cancer and statins, particularly lipophilic statins, and indicated that these associations were more pronounced for long duration. IMPACT: In a context of overdiagnosis and overtreatment, identifying factors associated with aggressive prostate cancers is important and could help improving targeted screening strategies.
No takes yet. Share an insight, caveat, or question.
Cordina‐Duverger et al. (2025) conducted a case-control in Prostate cancer (n=1,698). Statins vs. Non-use was evaluated on High-grade prostate cancer (ISUP score ≥4) (OR 0.52, 95% CI 0.27-1.00). Statin use was inversely associated with high-grade prostate cancer, with the effect being more pronounced for lipophilic statins and long-term use.
Synapse has enriched 10 related papers. Consider them for comparative context: